...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Personalized Medicine >Statin Pharmacogenomics: Opportunities to Improve Patient Outcomes and Healthcare Costs with Genetic Testing
【24h】

Statin Pharmacogenomics: Opportunities to Improve Patient Outcomes and Healthcare Costs with Genetic Testing

机译：Statin药物基因组学：通过基因测试改善患者结果和医疗保健成本的机会

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

HMG-CoA reductase inhibitors, commonly known as statins, are some of the most widely prescribed medications worldwide and have been shown to be effective at lowering cholesterol in numerous long-term prospective trials, yet there are significant limitations to their use. First, patients receiving statin therapy have relatively low levels of medication adherence compared with other drug classes. Next, numerous statin formulations are available, each with its own unique safety and efficacy profile, and it may be unclear to prescribers which treatment is optimal for their patients. Finally, statins have class-wide side effects of myopathy and rhabdomyolysis that have resulted in a product recall and dosage limitations. Recent evidence suggests that two genomic markers, KIF6 and SLCO1B1, may inform the therapy choice of patients initiating statins. Given the prevalence of statin usage, their potential health advantages and their overall cost to the healthcare system, there could be significant clinical benefit from creating personalized treatment regimens. Ultimately, if this approach is effective it may encourage higher adoption of generic statins when appropriate, promote adherence, lower rates of myopathy, and overall achieve higher value cardiovascular care. This paper will review the evidence for personalized prescribing of statins via KIF6 and SLCO1B1 and consider some of the implications for testing these markers as part of routine clinical care.
机译：HMG-CoA还原酶抑制剂，通常称为他汀类药物，是全球范围内处方最广泛的药物，在许多长期的前瞻性试验中已显示可有效降低胆固醇，但其使用存在明显局限性。首先，与其他药物类别相比，接受他汀类药物治疗的患者对药物的依从性较低。接下来，有许多他汀类药物制剂可供使用，每种制剂都有其独特的安全性和有效性，对处方者而言，尚不清楚哪种疗法最适合其患者。最后，他汀类药物具有肌病和横纹肌溶解的全类别副作用，导致产品召回和剂量限制。最近的证据表明，两个基因组标记物KIF6和SLCO1B1可能会为开始他汀类药物的患者提供治疗选择信息。鉴于他汀类药物的使用率，其潜在的健康优势以及其对医疗保健系统的总体成本，创建个性化的治疗方案可能会产生重大的临床收益。最终，如果这种方法有效，它可能会鼓励在适当的时候更多地采用他汀类药物，促进依从性，降低肌病发生率，并总体上获得更高价值的心血管护理。本文将回顾通过KIF6和SLCO1B1进行他汀类药物个性化处方的证据，并考虑作为常规临床护理的一部分测试这些标志物的一些含义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号